Pre-clinical mechanism
Pre-clinical literature describes BPC-157 as modulating the nitric oxide (NO) system, upregulating growth factor receptors (notably VEGFR2), and influencing angiogenic and fibroblastic pathways. In rodent injury models it has been associated with accelerated granulation tissue formation and altered expression of early growth response genes (egr-1, naB2).
Key pre-clinical findings
- Achilles tendon transection in rats: improved tendon-to-bone healing scores versus saline controls (Krivic et al., 2006).
- Medial collateral ligament transection model: faster macroscopic and histological ligament healing across a 14-day window (Cerovecki et al., 2010).
- Cysteamine-induced duodenal ulcer model: reduction in lesion area and improved mucosal regeneration markers (Sikiric et al., 2010).
- Muscle crush injury model: faster functional recovery and altered FAK-paxillin pathway expression (Novinscak et al., 2008).
Primary literature
Pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon
Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P · Journal of Orthopaedic Research · 2006
Pentadecapeptide BPC 157 positively affects both non-operated and operated Achilles tendon healing
Staresinic M, Sebecic B, Patrlj L, et al. · Journal of Orthopaedic Research · 2003
Stable gastric pentadecapeptide BPC 157 — novel therapy in gastrointestinal tract
Sikiric P, Seiwerth S, Rucman R, et al. · Current Pharmaceutical Design · 2011
BPC 157 and standard angiogenic growth factors (VEGFR2)
Hsieh MJ, Liu HT, Wang CN, et al. · Journal of Molecular Medicine · 2017